LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Crizotinib | 0.04 | uM | LJP5 | 2 | A24 | 72 | hr | 1311 | 4060 | 5100 | 0.7961 | 0.7802 |
MDA-MB-231 | Crizotinib | 0.04 | uM | LJP5 | 3 | A24 | 72 | hr | 1311 | 4288 | 5010 | 0.8557 | 0.8452 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 1311 | 4595 | 5128 | 0.8960 | 0.8914 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 1311 | 4441 | 5100 | 0.8708 | 0.8636 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 1311 | 4644 | 5010 | 0.9268 | 0.9229 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 1311 | 4380 | 5128 | 0.8541 | 0.8459 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 1311 | 4031 | 5100 | 0.7904 | 0.7737 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 1311 | 3998 | 5010 | 0.7979 | 0.7796 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 1311 | 4104 | 5128 | 0.8003 | 0.7858 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 1311 | 3697 | 5100 | 0.7249 | 0.6971 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 1311 | 3736 | 5010 | 0.7456 | 0.7183 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 1311 | 2233 | 5128 | 0.4354 | 0.3106 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 1311 | 2176 | 5100 | 0.4267 | 0.2948 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 1311 | 2209 | 5010 | 0.4408 | 0.3094 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 1 | A19 | 72 | hr | 1311 | 1278 | 5128 | 0.2492 | -0.0132 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 2 | A19 | 72 | hr | 1311 | 1222 | 5100 | 0.2396 | -0.0355 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 3 | A19 | 72 | hr | 1311 | 1242 | 5010 | 0.2479 | -0.0279 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 1 | D06 | 72 | hr | 1311 | 4706 | 4870 | 0.9663 | 0.9641 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 2 | D06 | 72 | hr | 1311 | 5148 | 4961 | 1.0376 | 1.0388 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 3 | D06 | 72 | hr | 1311 | 4891 | 4973 | 0.9834 | 0.9826 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 1 | D05 | 72 | hr | 1311 | 4546 | 4870 | 0.9334 | 0.9285 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 2 | D05 | 72 | hr | 1311 | 4464 | 4961 | 0.8997 | 0.8929 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 3 | D05 | 72 | hr | 1311 | 4944 | 4973 | 0.9940 | 0.9938 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 1 | D04 | 72 | hr | 1311 | 4589 | 4870 | 0.9423 | 0.9381 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 2 | D04 | 72 | hr | 1311 | 4664 | 4961 | 0.9400 | 0.9366 |